Program Catalog
Please find a list of all currently accredited Unique CritiqueTM programs listed below. Simply click on the title of any program to be taken to the course detail page where you will find additional program information, faculty biographies, accredtiation information, and the ability to participate in the program for credit!
Case-Based Assessments in Therapeutic Management of Multiple Sclerosis
Course Info:
- Release Date: October 1, 2009
- Expiration Date: September 30, 2011
- Accreditation: 1.5 Total hours
- Cost: Free
Abstract:
This program will discuss, compare and assess the evidence in therapeutic management of multiple sclerosis using interactive case-based learning technology. Attendees will receive a customized learning experience in a one-on-one question-and-answer format with expert faculty built upon case studies. Attendees will also be able to measure their answers against those of their peers. The program will provide information on immune modulating agents and their central role in MS management. It will... discuss rationale for early treatment of MS, issues in therapeutic adherence by patients with MS, risk versus benefit of treatment options, and strategies for treatment adjustments in the non-responder.
Guidelines-Based Management of HPV & Cervical Cytological Abnormalities
Course Info:
- Release Date: June 22, 2009
- Expiration Date: June 21, 2011
- Accreditation: 1.0 Total hours
- Cost: Free
Abstract:
New evidence for HPV testing and HPV diagnostics provides health care practitioners with improved techniques for detection of precancer. Knowledge of current guidelines for HPV testing and HPV diagnostics in women aged 30 and older is essential for practitioners in order to lower the risk of cervical cancer among their patients. This CME activity is intended to provide guidelines in the use of HPV testing and cervical cytological abnormalities. Practical application of the guidelines is provided... through case-based keyboard discussions between the expert faculty and the program participant, offering customized learning based upon the participant's responses to faculty questions. This one-on-one learning experience is designed to provide performance improvement in screening methods in HPV and cervical cancer for primary care physicians, family practice physicians, internists, gynecologists, nurse practitioners and physician assistants.
New Therapies, New Competencies in Managing Patients with Opioid Therapy
Course Info:
- Release Date: January 12, 2009
- Expiration Date: January 11, 2011
- Accreditation: 1.5 Total hours
- Cost: Free
Abstract:
The role of the community pharmacist in pain management is complex, including but not limited to monitoring and managing drug therapy, providing patient education, and providing drug information and education to other providers. When controlled substances are involved, the pharmacist is obligated to judge whether the prescription is legally valid and therapeutically appropriate. The emergence of pending therapeutic options in pain management will require the pharmacist to obtain accurate cli...nical updates. New abuse-deterrent therapy requires community pharmacists to recognize and appreciate issues of safety, efficacy, cost and social responsibility surrounding new and available therapy. The community pharmacist's legal responsibility to screen controlled substances for validity, their awareness of physician liability, and their obligation to social responsibility all weigh on the community pharmacist's need to achieve competence in current and emerging therapy to manage chronic pain.
Plotting a Course to Manage Rheumatoid Arthritis
Course Info:
- Release Date: October 15, 2007
- Expiration Date: October 15, 2008
- Accreditation: 1.0 Total hours
- Cost: Free
Abstract:
Rheumatoid arthritis (RA) is a progressive, debilitating, and sometimes crippling condition which has a tremendous burden on society and the workforce. Patients with RA may suffer from complications related to joint pathology as well as organ dysfunction, including decreased immune system function, increased cardiovascular risk, and pulmonary complications. In light of this evidence, it is important to consider appropriate and early treatment of this condition. There are many effective therapies presently available to treat RA, including analgesics, anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, and anti-tumor necrosis factor (anti-TNF) drugs. Data suggests that early treatment with these newer agents may forestall the progression of the joint damage seen in patients with RA; however, there have been concerns regarding their long-term safety. This educational program will discuss the appropriate treatment of RA and the role that newer agents have in its management. Considerations regarding safety, efficacy, long-term therapy and cost will be discussed.
Plotting a Course to Manage Inflammatory Bowel Disease
Course Info:
- Release Date: October 15, 2007
- Expiration Date: October 15, 2008
- Accreditation: 1.0 Total hours
- Cost: Free
Abstract:
Inflammatory bowel disease (IBD) consists of 2 very distinct entities: Crohn’s disease and ulcerative colitis. Both conditions have severe symptoms, including abdominal cramping, diarrhea, and rectal bleeding. Both are also associated with a multitude of complications, including an increased risk of colon cancer in patients afflicted with the disease for long periods of time. Because these conditions can affect patients who are of working age, there is a disproportionate effect of IBD on younger patients and those enrolled in the workforce. As a result, proper treatment is essential, and includes anti-inflammatory drugs, sulfasalazine, and immunomodulatory drugs. The newest class of drugs to be utilized in patients with IBD is the anti-tumor necrosis factor (anti-TNF) drug, which has been shown to be highly effective in relieving the signs and symptoms of IBD, particularly in patients with more severe disease. This program will discuss the proper management of patients with IBD, including a focus on newer therapies and their relative safety and efficacy.